Miscellaneous ePI Test, published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cander2/epi-test/ and changes regularly. See the Directory of published versions
Inlyta®
Axitinib
1 mg
5 mg
Film coated tablets
Reference Market: European Union/ US indication
Hybrid Label
PACKAGE LEAFLET
Package leaflet: Information for the patient
Inlyta 1 mg film-coated tablets
Inlyta 5 mg film-coated tablets
Axitinib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
Inlyta is a medicine containing the active substance axitinib. Axitinib reduces the blood supply to the tumour and slows down the growth of cancer.
Inlyta is indicated for the treatment of advanced kidney cancer (advanced renal cell carcinoma) in adults, when one prior drug treatment for this disease has not worked.
If you have any questions about how this medicine works or why this medicine has been prescribed for you, ask your doctor.
Do not take Inlyta:
If you are allergic to axitinib or any of the other ingredients of this medicine (listed in section 6).
If you think you may be allergic, ask your doctor for advice.
Warnings and precautions
Talk to your doctor or nurse before taking Inlyta
Inlyta can raise your blood pressure. It is important to check your blood pressure before you take this medicine, and regularly while you are taking it. If you have high blood pressure (hypertension) you may be treated with medicines to reduce the blood pressure. Your doctor should make sure that your blood pressure is under control before starting Inlyta treatment, and while on treatment with this medicine.
Inlyta can cause thyroid gland problems. Tell your doctor if you get tired more easily, generally feel colder than other people, or your voice deepens whilst taking this medicine. Your thyroid function should be checked before you take Inlyta and regularly while you are taking it. If your thyroid gland is not producing enough thyroid hormone before, or while on treatment with this medicine, you should be treated with thyroid hormone replacement.
Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes; or dizziness while on treatment with this medicine.
Inlyta may increase your chance of bleeding. Tell your doctor if you have any bleeding, coughing up of blood or bloody sputum while on treatment with this medicine.
Inlyta may increase the risk of developing a hole in the stomach or intestine or formation of fistula (abnormal tube-like passage from one normal body cavity to another body cavity or the skin).
Tell your doctor if you have severe abdominal pain while on treatment with this medicine.
Your doctor should stop Inlyta at least 24 hours before your operation as it may affect wound healing. Your treatment with this medicine should be restarted when the wound has adequately healed.
Get emergency help right away and call your doctor. This could be a rare neurological side effect named posterior reversible encephalopathy syndrome.
Your doctor should do blood tests to check your liver function before and during treatment with Inlyta.
Inlyta may increase the risk of developing heart failure events. Your doctor should monitor for signs or symptoms of heart failure events periodically throughout treatment with axitinib.
Use in children and adolescents
Inlyta is not recommended for people aged under 18. This medicine has not been studied in children and adolescents.
Other medicines and Inlyta
Some medicines may affect Inlyta, or be affected by it. Please tell your doctor, pharmacist or nurse about all the medicines you have recently taken, are currently taking, or plan to take, including medicines obtained without a prescription, vitamins, and herbal medicines. The medicines listed in this leaflet may not be the only ones that could interact with Inlyta.
The following medicines may increase the risk of side effects with Inlyta:
The following medicines may reduce the effectiveness of Inlyta:
You should not take these medicines during your treatment with Inlyta. If you are taking any of them, tell your doctor, pharmacist or nurse. Your doctor may change the dose of these medicines, change the dose of Inlyta, or switch you to a different medicine.
Inlyta may increase side effects associated with theophylline, used to treat asthma or other lung diseases.
Inlyta with food and drink
Do not take this medicine with grapefruit or grapefruit juice, as it may increase the chance of side effects.
Pregnancy and breast-feeding
Driving and using machines
If you experience dizziness and/or feel tired while on treatment with Inlyta, take special care when driving or using machines.
Inlyta contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Inlyta contains sodium
This medicine contains less than 1 mmol (23 mg) sodium per film-coated tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. You should check with your doctor, pharmacist or nurse if you are not sure.
The recommended dose is 5 mg twice a day. Your doctor may subsequently increase or decrease your dose depending on how you tolerate treatment with Inlyta.
Swallow the tablets whole with water, with or without food. Take the Inlyta doses approximately 12 hours apart.
If you take more Inlyta than you should
If you accidentally take too many tablets or a higher dose than you need, contact a doctor for advice right away. If possible, show the doctor the pack, or this leaflet. You may require medical attention.
If you forget to take Inlyta
Take your next dose at your regular time. Do not take a double dose to make up for the forgotten tablets.
If you vomit while taking Inlyta
If you vomit, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.
If you stop taking Inlyta
If you are not able to take this medicine as your doctor prescribed or you feel you do not need it anymore, contact your doctor right away.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects could be serious. You must immediately contact your doctor if you experience any of those following serious side effects (see also section 2 “What you need to know before you take Inlyta”):
Other side effects with Inlyta may include:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Not known: frequency cannot be estimated from the available data
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.
Do not use this medicine after the expiry date which is stated on the carton and on the blister foil or bottle after “EXP”. The expiry date refers to the last day of the month.
What Inlyta contains
Inlyta 1 mg: each tablet contains 1 mg axitinib
Inlyta 5 mg: each tablet contains 5 mg axitinib
What Inlyta looks like and contents of the pack
Inlyta 1 mg film-coated tablets are red, oval and debossed with “Pfizer” on one side and “1 XNB” on the other. Inlyta 1 mg is available in bottles of 180 tablets and blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.
For the pack of 56 tablets, the pack contains 4 blisters each blister has 14 film coated tablets (4 X 14).
Inlyta 5 mg film-coated tablets are red, triangular and debossed with “Pfizer” on one side and “5 XNB” on the other. Inlyta 5 mg is available in bottles of 60 tablets and blisters of 14 tablets. Each blister pack contains 28 tablets or 56 tablets.
For the pack of 56 tablets, the pack contains 4 blisters each blister has 14 film coated tablets (4 X 14).
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Manufacturer
Pfizer Manufacturing Deutschland GmbH
Betriebsstätte Freiburg
Mooswaldallee 1
79090 Freiburg
Germany
This leaflet was last approved in
EU: October 2020
THIS IS A MEDICAMENT
Keep all medicaments out of reach and sight of children Council of Arab Health Ministers Union of Arabic Pharmacists |
status: active
Domain: Human use
Combined pharmaceutical dose form:
Legal Status of Supply: Medicinal product subject to medical prescription
Clinical Information